세포 동역학, 통합
US ˙ NasdaqGS ˙ US23282W6057

SecurityCYTK / Cytokinetics, Incorporated
InstitutionAlps Advisors Inc
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Alps Advisors Inc closes position in CYTK / Cytokinetics, Incorporated

On February 12, 2026 - Alps Advisors Inc filed a 13F-HR form disclosing ownership of 0 shares of Cytokinetics, Incorporated (US:CYTK) valued at $0 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 5, 2025 disclosing 56,619 shares of Cytokinetics, Incorporated. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-12 2025-12-31 13F CYTOKINETICS COM NEW 23282W605 0 -100.00 0
2025-11-05 2025-09-30 13F CYTOKINETICS COM NEW 23282W605 56,619 -7,773 -12.07 3,112 46.26 0.0166
2025-08-11 2025-06-30 13F CYTOKINETICS COM NEW 23282W605 64,392 64,392 2,128 0.0123
2023-08-14 2023-06-30 13F CYTOKINETICS COM NEW 23282W605 0 -62,694 -100.00 0 -100.00
2023-05-10 2023-03-31 13F CYTOKINETICS COM NEW 23282W605 62,694 -1,433 -2.23 2,206 -24.91 0.0195
2023-02-14 2022-12-31 13F CYTOKINETICS COM NEW 23282W605 64,127 12,727 24.76 2,938 17.99 0.0262
2022-11-14 2022-09-30 13F CYTOKINETICS COM NEW 23282W605 51,400 588 1.16 2,490 24.75 0.0236
2022-08-15 2022-06-30 13F/A-1 CYTOKINETICS COM NEW 23282W605 50,812 -35,396 -41.06 1,996 -37.09 0.0194
2022-08-11 2022-06-30 13F CYTOKINETICS COM NEW 23282W605 50,812 -35,396 1,996 0.0194
2022-05-16 2022-03-31 13F CYTOKINETICS COM NEW 23282W605 86,208 -10,863 -11.19 3,173 -28.28 0.0344
2022-02-09 2021-12-31 13F CYTOKINETICS COM NEW 23282W605 97,071 -5,283 -5.16 4,424 20.94 0.0498
2021-11-15 2021-09-30 13F CYTOKINETICS COM NEW 23282W605 102,354 7,862 8.32 3,658 95.61 0.0352
2021-08-11 2021-06-30 13F CYTOKINETICS COM NEW 23282W605 94,492 -34,160 -26.55 1,870 -37.50 0.0165
2021-05-07 2021-03-31 13F CYTOKINETICS COM NEW 23282W605 128,652 1,214 0.95 2,992 12.99 0.0292
2021-02-03 2020-12-31 13F CYTOKINETICS COM NEW 23282W605 127,438 127,438 2,648 0.0298
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.